2016 - Page 3 of 3 - MS-Docblog

Is the Number of MS Patients Increasing?

21. March 2016 Prof. Dr. med. Mathias Mäurer General

How many are there actually? It is indeed an exciting question, how many people in the Federal Republic are affected by MS. If you consult a textbook, it often states a number of 120,000 affected.

Paroxysmal or Chronically Progressive – Further Information

7. March 2016 Prof. Dr. med. Mathias Mäurer Therapy for MS

I was pleased by the interest that my last post about the course of MS has generated – the article was shared quite often and there have not been so many comments shortly after going

A common question: relapsing or chronic-progressive?

4. March 2016 Prof. Dr. med. Mathias Mäurer General

I am often asked in the consultation hour: “Do I now have a relapsing or a chronic-progressive course.” And usually, this question is posed by younger patients who have recently been diagnosed with MS. There

Bladder Dysfunction in Advanced Stages of MS

24. February 2016 Prof. Dr. med. Mathias Mäurer General

While the spastic bladder is still quite accessible to drug therapies, more complex bladder dysfunctions, which mainly characterize later stages of MS, are no longer so easy to treat.

Bladder Dysfunction: The Spastic Bladder – A Common Problem in Early MS

17. February 2016 Prof. Dr. med. Mathias Mäurer MS Symptoms

Bladder dysfunction is among the most common and perhaps also the most underestimated symptoms of MS. It can be assumed that up to 80% of those affected by MS develop problems with the bladder during

Pregnancy under Tysabri therapy – how should one proceed?

5. February 2016 Prof. Dr. med. Mathias Mäurer General, MS Therapy

I had already written about the topic of pregnancy in women with mild/moderate MS in the context of this blog. In doing so, I had excluded women with highly active MS – so explicitly also

Extending the Infusion Intervals of Tysabri – a Sensible Measure in MS?

1. February 2016 Prof. Dr. med. Mathias Mäurer General, Therapy for MS

Tysabri (active ingredient Natalizumab) is given for (highly-) active Multiple Sclerosis every 4 weeks. Recently, it has been frequently mentioned that extending the infusion interval – often the number 8 weeks is mentioned – reduces

Melatonin and MS

7. January 2016 Prof. Dr. med. Mathias Mäurer General

The results on melatonin and MS are interesting from my point of view, mainly because they show us how complex the interaction between environmental factors and the development or course of MS is – and

Year: 2016

Is the Number of MS Patients Increasing?

Paroxysmal or Chronically Progressive – Further Information

A common question: relapsing or chronic-progressive?

Bladder Dysfunction in Advanced Stages of MS

Bladder Dysfunction: The Spastic Bladder – A Common Problem in Early MS

Pregnancy under Tysabri therapy – how should one proceed?

Extending the Infusion Intervals of Tysabri – a Sensible Measure in MS?

Melatonin and MS

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community